Spiral CT pulmonary angiography is an effective way of demonstrating pulmonary embolism in segmental and larger arteries. 1 The basic sign of a filling defect within a well opacified pulmonary artery is straightforward enough. The case report by Oliver et al 2 highlights the fact that there may be ancillary signs of pulmonary embolism on spiral CT scanning—in this case shift of the interventricular septum—which corroborates the diagnosis and, more controversially, provides prognostic information. Shift of the interventricular septum and other signs of right ventricular dysfunction are readily demonstrated on echocardiography, but in cases of suspected pulmonary embolism echocardiography does not provide the breadth of information of a spiral CT examination. For example, additional signs of pulmonary embolism, including a mosaic perfusion pattern of the lung parenchyma and radiographically cryptic pleural effusions or small pulmonary infarcts, can be readily picked up on spiral CT scanning. Conversely, because spiral CT scanning provides the “big picture”, an alternative diagnosis may be shown by spiral CT scanning in up to one third of patients investigated for suspected pulmonary embolism. 3

The application of image processing to volumetric spiral CT data can be broadly divided into graphic 3-D realisations—for example, virtual reality bronchoscopy 4—and the rendering of data so that it is suitable for quantitative analysis. However, progress towards routine volumetric (3-D) depictions of spiral CT data is likely to be slow. 5 Even at this early stage of development it is possible to extract very precise volumetric measures of abnormal lung; the most obvious application is in the quantification of low attenuation lung (corresponding to emphysema) on inspiratory and expiratory spiral CT scans. Early results have shown remarkably good correlation between the extent of low attenuation lung derived from 3-D reconstructions of the lungs with functional indices of air flow obstruction and air trapping. 6 With this new technique the entire lungs are evaluated, unlike the conventional “density mask” approach which can be applied only to individual CT sections, (which introduces problems with sampling). With the powerful combination of volumetric data from spiral CT scanning and advanced image processing, the excitement has only just begun.


Commentary

David M Hansell

The common feature of the reports by Franco et al 1 and Oliver et al 2 is the use of spiral (or volumetric) computed tomography to demonstrate features which would not be readily identifiable on conventional computed tomographic (CT) scanning. The advantages of spiral CT over conventional CT scanning are twofold: increased speed of data acquisition and volumetric (rather than slice by slice) data acquisition. The attribute of speed means that most thoracic examinations can be performed within a single breath hold and the timing of intravenous contrast administration can be precisely tailored, thus allowing reproducible enhancement of any desired part of the vasculature—for example, the pulmonary arteries in cases of suspected pulmonary embolism. Because an entire volume of data is acquired (with almost equal spatial resolution in the three axes) it is possible to reconstruct images in any plane, including three-dimensional (3-D) reconstructions. 3 Most examinations acquired with spiral CT scanning are presented as a series of transaxial slices, reflecting the traditional presentation of conventional CT images.

In the report by Franco et al 1 the clarity with which the anomalous arteries feeding the sequestrated lung are shown on the 3-D reconstructions is striking. In the past a separate preoperative examination (either aortography or possibly magnetic resonance angiography) to identify the vascular supply would have been regarded as mandatory. Other imaging tests such as radionuclide scintigraphy or ultrasound may answer specific questions in cases of pulmonary sequestration, but the wealth of information now available from a single spiral CT examination is remarkable. Quite apart from their aesthetic appeal, the main benefit of these readily produced 3-D reconstructions is an easy appreciation of what can be complex anatomy. Nevertheless, claims for the increased diagnostic gain from these 3-D reconstructions should not be too extravagant: the anomalous vessels would be identifiable on images presented in the standard transaxial format, although without such immediacy. Furthermore, demonstration of the venous drainage into the pulmonary circulation (for the classic intralobar sequestrations) may not be so readily obtained with a single spiral CT examination. However, the ability to extract so much information from a spiral CT examination represents a substantial advance on conventional CT scanning.
Diagnosis of pulmonary sequestration by spiral CT angiography

José Franco, Roberto Aliaga, María L Domingo, Pedro Plaza

Abstract
The diagnosis of pulmonary sequestration traditionally requires arteriography to identify abnormal systemic vessels feeding the abnormal portion of the lung. Non-invasive imaging techniques have recently been used to replace arteriography. Conventional computed tomographic (CT) scanning is, however, at a disadvantage because of its inability to obtain multiplanar images. The combination of spiral CT scanning and computerised three-dimensional reconstruction (spiral CT angiography) can be used to visualise the anatomical detail of a wide range of vessels within the lung. Four cases of pulmonary sequestration are reported which were successfully diagnosed using spiral CT angiography. Spiral CT scanning allows simultaneous imaging of abnormal vessels and lung parenchyma in a single examination and is particularly useful in the diagnosis and assessment of pulmonary sequestration.

Keywords: pulmonary sequestration; spiral computed tomography

Pulmonary sequestration is a rare congenital pulmonary disorder defined as an area of dysplastic and non-functioning pulmonary tissue with an anomalous systemic blood supply. It has been classically described in two forms—intralobar sequestrations located within the visceral pleura and surrounded by normal lung, and extralobar sequestrations which have a separate pleural covering. Both types are supplied with blood from the aorta or its branches. The venous return of the intralobar sequestration is usually via the pulmonary veins while extralobar sequestrations generally have systemic venous drainage. Nevertheless, many variations and combinations of these classical patterns have been described. Traditionally, the diagnosis of pulmonary sequestration requires arteriography to identify abnormal systemic vessels feeding the abnormal portion of the lung. More recently, other procedures have been advocated as a less invasive means of identifying the anomalous artery. Although conventional computed tomographic (CT) scanning can show both abnormal lung parenchyma and the systemic arterial supply, it lacks the multiplanar images which limits its usefulness in the diagnosis of sequestration. With the advent of helical technology, spiral CT angiography is able to delineate the aorta and its branches. The role of CT scanning in evaluating suspected pulmonary sequestration should therefore be re-evaluated.

In this report we describe the use of spiral CT angiography to image the aberrant systemic artery in four cases of pulmonary sequestration.

Methods
We performed four CT angiography studies with a PQ2000S helical scanner (Picker International Inc, Highlands Heights, Ohio, USA). Spiral volumetric CT scanning was performed with 4 mm slide thickness, 4 mm table speed, 3 mm reconstruction index, and smooth reconstruction algorithm. A non-ionic contrast medium (120 ml, iodine 300 mg/ml) was administered at a rate of 3 ml/s via the antecubital vein.

Figure 1  Spiral CT scan of case 1. (A) Contrast enhanced CT axial image showing the small aberrant artery (arrow) adjacent to the upper abdominal aorta (a). (B) Anterior view of helical CT angiogram. The anomalous artery (arrow) feeding the pulmonary lesion (L) arises from the coeliac axis.
A 25 second scan delay was used in order to optimise contrast in the systemic arterial phase of the study. Three-dimensional reconstruction (3D) was performed with a Voxel Q workstation using a shaded surface display (SSD) program with segmentation option.

Case reports

CASE 1
A 32 year old man with a 34 pack-year history of cigarette smoking who still smoked two packs a day was admitted to the smoking cessation programme at our hospital. There was a history of pneumonia at the age of 14. A chest radiograph showed localised air trapping in the left lower lobe. A spiral CT scan (fig 1) revealed a multicystic lesion in the posterior basal segment of the left lower lobe supplied by an artery derived from the coeliac axis; venous return to the pulmonary veins was also demonstrated. The presence of the anomalous systemic artery and venous drainage was confirmed by aortography. The patient was asymptomatic and refused surgery.

CASE 2
A 28 year old man presented with a one month history of recurrent haemoptysis. He smoked one pack of cigarettes daily. Chest radiography showed a mass, 4 cm in diameter, in the right lower lobe. Bronchoscopic examination indicated that the source of bleeding was the right lower lobe but no endobronchial lesions were seen. A spiral CT scan (fig 2) revealed a homogeneous mass in the right lower lobe contiguous to the diaphragm and identified its anomalous arterial supply derived from the upper abdominal aorta just above the coeliac artery; venous drainage into the pulmonary veins was also visualised. Intralobar pulmonary sequestration was confirmed by aortography and thoracic surgery.

CASE 3
A 65 year old male cigarette smoker had a two week history of productive cough and fever. The patient improved with antibiotic therapy but a persistent cough developed. Radiography of the chest showed partial collapse of the left lower lobe and a mass like opacity with an air-fluid level. A CT scan demonstrated a non-homogeneous mass with multiple cystic appearing spaces and cavitation involving the posterior basal segment of the left lower lobe. Fibreoptic bronchoscopic examination disclosed no abnormality. A percutaneous fine needle aspiration biopsy specimen of the lesion revealed non-diagnostic findings. Spiral CT angiography (fig 3) showed a feeding systemic artery arising from the descending thoracic aorta and venous drainage to the pulmonary veins. At surgery an infected intralobar sequestration was found.

CASE 4
A 41 year old man was admitted to hospital with a 48 hour history of fever and pleuritic chest pain. There was no history of use of tobacco. Chest radiography revealed a homogeneous density in the right lower lobe. He was diagnosed as having pneumonia and treated with clarithromycin. One month later he was
Diagnosis of pulmonary sequestration by spiral CT angiography

1091

...the left lung than in the right.2 The blind end...lower lobes. It occurs slightly more often in...predilection for the posterior basal segment of...counts for 73% of all sequestrations and has a...characteristically involves the lower lobes of the...Both intralobar and extralobar sequestration...Discussion

In all four cases described in this report spi...sequestrations are frequently discovered during...the neonatal period in infants with other...The clinical picture is usually dominated by the...although infection can occur, especially if there...is a communication with the oesophagus or the...In case 1 pulmonary sequestration was...detected by routine radiography, while in case...2 haemoptysis was the presenting symptom of...an intralobar sequestration. Case 3 had an...intralobar sequestration typically manifested...by symptoms of infection and case 4 had con...comitant disseminated tuberculosis.

Plain radiographs of the chest often show a...single homogeneous opacity or, less commo...nally, a cystic mass in the base of one lung th...at can sometimes suggest the diagnosis of sequestration.1 Less specific findings include...recurrent pneumonia and focal bronchiectatic...changes. The principal objective for diag...nosis of pulmonary sequestration is to identify...the systemic artery supply. With this information,...imaging can distinguish sequestration from...other causes of lung opacity. Because accessory...arteries, pleural investment, and venous drain...age are adequately determined intraopera...tively, at some institutions only the presence...and location of an aberrant systemic artery are...considered essential for preoperative assess...ment for any symptomatic pulmonary sequestration.1

Imaging strategies for suspected pulmonary sequestration are based on case reports or...small series since it is a rare congenital disorder and no study exists that objectively compares...imaging techniques for detection, definition, or...cost effectiveness.4 Since the definitive step in...the diagnosis of sequestration is the demon...stration of the systemic arterial supply, for a...long time diagnosis was made by conventional...angiography. More recently all imaging tech...niques capable of showing the artery have been...implicated in evaluating sequestration. Magnetic...resonance (MR) imaging and MR angiogra...phy can be used together to diagnose pulmon...ary sequestration in a single non-invasive exam...ination.6 Nevertheless, MR cannot accurately...evaluate lung parenchyma and the airways and must be considered in terms of...cost and availability. Sonography requires a...favourable acoustic window and is ideally su...ited for evaluating the chest prenatally and...postnatally.7 Other non-invasive techniques for...evaluation of sequestration such as scintigra...phy are only rarely necessary.

In all four cases described in this report spi...ral CT angiography successfully delineated...the origin and course of the anomalous systemic...artery. Axial images were enough to make the...diagnosis but three-dimensional reconstruc...tion aided both radiologists and referring cli...nicians by demonstrating anatomical relation...ships, particularly for vessels orientated in the...axis.8 On the other hand, venous drainage was...also identified in the three cases in which lower...pulmonary veins were included in contrast...enhanced helical CT scans. We have performed...
Interventricular septal shift due to massive pulmonary embolism shown by CT pulmonary angiography: an old sign revisited

T B Oliver, J H Reid, J T Murchison

Abstract

The computed tomographic (CT) pulmonary angiogram appearances of acute right ventricular dysfunction due to massive pulmonary embolus in a patient are described. Abnormal findings comprised right ventricular dilatation, interventricular septal shift, and compression of the left ventricle. These changes resolved following thrombolysis. Use of CT pulmonary angiography to diagnose pulmonary emboli is increasing. Secondary cardiac effects are established diagnostic features shown by echocardiography. These have not been previously described but are important to recognise as they may carry important prognostic and therapeutic implications.

(Thorax 1998;53:1092–1094)

Keywords: pulmonary embolism; right ventricular dysfunction; spiral computed tomography; pulmonary angiography

A 43 year old man collapsed while out walking. On admission to hospital he was dyspnoeic and cyanosed. On direct questioning he admitted to right leg pain. Examination showed that his heart rate was 105 beats/min, respiratory rate was 28 breaths/min, and blood pressure was 100/60 mm Hg. His jugular venous pressure was raised but examination was otherwise normal. Electrocardiography demonstrated sinus tachycardia; the chest radiograph was normal. Measurement of arterial blood gas tensions confirmed hypoxaemia with hypocapnia (P\textsubscript{O\textsubscript{2}} 8 kPa on 6 l/min oxygen, P\textsubscript{CO\textsubscript{2}} 4 kPa). An echocardiogram demonstrated dilatation of the right ventricle. The clinical features of syncope, cyanosis and dyspnoea with engorged neck veins in a patient with a normal chest radiograph and clinical suspicion of deep venous thrombosis led to a presumptive diagnosis of pulmonary embolus.

A computed tomographic (CT) pulmonary angiogram was performed. A 3 mm spiral scan, reconstructed at 1.5 mm intervals, was undertaken on a Hi Speed Advantage scanner (General Electric Medical Systems, Milwaukee, Wisconsin, USA) using 150 ml of contrast (200 mg I/ml) at 4 ml/s. This showed multiple pulmonary emboli within the main and segmental pulmonary arteries. In addition there was dilatation of the right ventricle and atrium with normal wall thicknesses, the interven-
Interventricular septal shift due to pulmonary embolism on CT angiogram

The initial abrupt rise in pulmonary artery pressure causes increased right ventricular afterload which results in right ventricular dilatation and dyskinesia. Secondary effects of this are tricuspid regurgitation, right atrial enlargement, and loss of respiratory variation in caliber of the great veins. Increased right ventricular wall tension may reduce local coronary blood flow, resulting in ischemia which impairs right ventricular function further. As the right ventricle dilates, the interventricular septum is displaced towards the left ventricle, the right ventricle assuming a circular axial configuration and the left ventricle a crescentic appearance more typical of the normal right ventricle. This septal shift, combined with the constraining influence of the pericardium, results in reduced left ventricular filling which is already compromised by reduced preload. The cardiac output falls.

Signs documenting this sequence such as right ventricular dilatation and hypokinesis (which may spare the apex), abnormal interventricular septal motion, pulmonary artery dilatation, tricuspid regurgitation, and loss in respiratory variation in inferior vena caval diameter can be detected at echocardiography. Echocardiographic assessment of the right ventricle has been recommended as an integral part of the investigative algorithm for suspected acute pulmonary embolus published recently by the British Thoracic Society working party. Right ventricular dysfunction is an umbrella term which also includes more subjective echocardiographic findings such as abnormalities of the motion of the right ventricular wall. These findings are often encountered in lesser degrees of pulmonary embolus and have led to debate over the significance of the more objective signs. Acute right ventricular dilatation and interventricular septal shift have been associated specifically with massive pulmonary embolism and reversible septal displacement has been described in a series of patients requiring aggressive treatment for circulatory failure due to massive pulmonary embolism.

Thrombolysis is an accepted treatment in massive life threatening pulmonary embolus and its administration in the case described here was associated with a rapid return of pulmonary and systemic arterial pressures towards normal. Recognition of the signs presented by CT scanning or echocardiography allows more aggressive therapy to be targeted to individuals at greatest risk.

CT pulmonary angiography is increasingly used to diagnose pulmonary embolus. It is non-invasive and quick to perform. In the case described the patient was imaged directly after initial assessment in the emergency room and spent less than 15 minutes in the imaging suite. Comparative studies have shown excellent correlation between CT and conventional pulmonary angiography in the detection of emboli in segmental or larger vessels and in many centres the technique has largely replaced conventional pulmonary angiography. Secondary signs of pulmonary embolus have not, to our knowledge, been described at CT pulmonary angiography. The interventricular septum is usually...
LETTERS TO THE EDITOR

Cardiac risks with β agonists

Martin et al suggest that caution should be exercised when prescribing long acting oral β agonists to patients at risk of cardiac failure, based on results from a prescription event monitoring (PEM) study. Firstly, all β agonists (short and long acting, oral and inhaled) should be used with caution in patients with severe cardiovascular disease, as is pointed out in the package insert for all drugs of this class.

Secondly, the study does not provide any evidence on this issue. PEM studies are not designed to study causal relations but to generate new hypotheses. Although the authors have made an attempt to consider several potential biases in the analyses, the study design is inappropriate compared with, for example, a prospective randomised controlled trial, and the results must be interpreted with great caution.

Thirdly, no support for an association between bambuterol and an increased risk for cardiac failure has been found in our review of preclinical studies, clinical studies (including >3000 patients/healthy volunteers), or post-marketing surveillance (based on >130 million treatment days).

Fourthly, according to the authors there have been no spontaneous reports of cardiac failure with bambuterol to the Committee on Safety of Medicines. This is in agreement with the WHO database Intdis, with no reports of cardiac failure for bambuterol.

Finally, the paper suggests a doubled asthma mortality in patients receiving salmeterol. In our opinion the reported higher relative risk for non-fatal cardiac failure for bambuterol and the doubled asthma mortality for salmeterol both appear equally explicable by factors other than direct causality, such as confounding by concomitant diseases and disease severity.

Thus, PEM data may be of help in identifying signals with new drugs, but there is little if any merit in comparing drugs used in different populations and introduced to the market at different times.

Table 1 Rates of cardiac failure during the first month of exposure to bambuterol or a cardiovascular drug studied by prescription event monitoring (PEM)

<table>
<thead>
<tr>
<th>Drug* (ranked by rate)</th>
<th>No. of patients with reported cardiac failure during month 1</th>
<th>No. of patient-months at exposure during month 1</th>
<th>Rate (events per 1000 patient-months of exposure)</th>
<th>Mean (SD)</th>
<th>Males (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Xamoterol 97</td>
<td>4 463</td>
<td>21.7</td>
<td>70.8 (13.9)</td>
<td>53.0</td>
<td></td>
</tr>
<tr>
<td>Nicorandil 73</td>
<td>1 157</td>
<td>6.3</td>
<td>66.9 (11.2)</td>
<td>61.1</td>
<td></td>
</tr>
<tr>
<td>Bambuterol 29</td>
<td>5 891</td>
<td>4.9</td>
<td>58.5 (18.6)</td>
<td>44.8</td>
<td></td>
</tr>
<tr>
<td>Losartan 53</td>
<td>12 900</td>
<td>4.1</td>
<td>63.5 (12.1)</td>
<td>40.2</td>
<td></td>
</tr>
<tr>
<td>Diltiazem 24</td>
<td>8 808</td>
<td>2.7</td>
<td>62.3 (13.9)</td>
<td>59.3</td>
<td></td>
</tr>
<tr>
<td>Enalapril 33</td>
<td>13 544</td>
<td>4.9</td>
<td>61.2 (14.9)</td>
<td>46.1</td>
<td></td>
</tr>
<tr>
<td>Perindopril 17</td>
<td>8 368</td>
<td>2.0</td>
<td>61.8 (12.7)</td>
<td>45.0</td>
<td></td>
</tr>
<tr>
<td>Nicardipine 17</td>
<td>9 517</td>
<td>1.8</td>
<td>62.9 (13.9)</td>
<td>48.4</td>
<td></td>
</tr>
<tr>
<td>Lisinopril 18</td>
<td>11 574</td>
<td>1.6</td>
<td>60.9 (14.3)</td>
<td>44.0</td>
<td></td>
</tr>
<tr>
<td>Ramipril 2</td>
<td>1 277</td>
<td>1.6</td>
<td>60.5 (12.4)</td>
<td>45.1</td>
<td></td>
</tr>
<tr>
<td>Amlodipine 12</td>
<td>12 085</td>
<td>1.0</td>
<td>61.8 (14.7)</td>
<td>46.9</td>
<td></td>
</tr>
</tbody>
</table>

*Betaxolol, doxazosin, isradipine not shown as number of patients with event was <2, or rate was <1.0 per 1000 patient-months of exposure.


Bertil Lindmark
Department of Clinical Drug Safety and Epidemiology, Clinical REID, Astra Draco, S221 00 Lund, Sweden

AUTHORS' REPLY Bertil Lindmark of Astra Draco makes five points about our study on the risk of non-fatal cardiac failure and ischaemic heart disease with long acting β agonists. Firstly, he points out that all β agonists should be used with caution in patients with severe cardiovascular disease. The cardiac effects of β agonists are well described,1 but there is limited evidence available on whether or not the risks of adverse cardiac effects differ depending on the dose and method of administration of the drug. Clearly, these are important questions for prescribing doctors faced with treating asthmatic patients with concomitant cardiac disease. An observational cohort study formed from health insurance databases from the Province of Saskatchewan, Canada found an increased relative risk of death from cardiovascular disease in users of β agonists taken orally or by nebuliser, but not in users of β agonists administered by metered dose inhaler.2 The deaths occurred in patients with significant cardiac disease, suggesting that β agonists taken orally or by nebuliser should be avoided in patients at high risk of cardiovascular events. We found that the oral β agonist bambuterol, but not the inhaled β agonist salmeterol, was associated with an increased risk of non-fatal cardiac failure. The results from both these studies are plausible as oral β agonists provide a greater systemic dose than that achieved with metered dose inhalers3 and tachycardia and prolonged Q-T interval have been reported principally with nebulised or oral β agonists.4 The advised total daily dose of oral bambuterol..."
(20 mg) is 200 times that of inhaled salmeterol (100 μg). Secondly, Dr Lindmark reiterates our point that the results must be interpreted with caution because the study was observational, and more definitive evidence would come from a prospective randomised trial. Nevertheless, hypotheses about drug safety concerns are often generated from observational studies. Such studies drive further research because they provide an “a priori” hypothesis and lay the formulation of a clinically relevant end point. Until results from prospective trials become available, observational research using cohort or case-control techniques remains an important source of evidence about the safety of drugs. Thirdly, he states that a review by Astra Draco has found no evidence from pre-marketing or post-marketing studies of an association between bambuterol and cardiac failure. In general, pre-marketed drugs have their own limitations, as evidenced by the recent withdrawal on safety grounds of two newly launched drugs. Similarly, different types of post-marketing surveillance studies, including PEM, have different advantages and disadvantages and, in general, one system cannot be relied upon to provide all the evidence needed. This point also applies to the fourth comment. In particular, it should be noted that there is gross under-reporting of suspected adverse drug reactions to the Committee on Safety of Medicines and other regulatory authorities, and there are many difficulties associated with interpreting data from spontaneous reporting schemes.

Finally, as is stated clearly in our paper, it is possible that the association may be explained by factors such as confounding by concomitant disease and disease severity. Interestingly, the rate of cardiac failure associated with bambuterol in the first month of treatment was higher than for 11 cardiovascular drugs previously studied by PEM (table 1). Only two cardiac drugs, including the inotropic sympathomimetic xamoterol (table 1). However, the inotropic sympathomimetic xamoterol (table 1). Only two cardiac drugs, including the inotropic sympathomimetic xamoterol, have different advantages and disadvantages and, in general, one system cannot be relied upon to provide all the evidence needed. This point also applies to the fourth comment. In particular, it should be noted that there is gross under-reporting of suspected adverse drug reactions to the Committee on Safety of Medicines and other regulatory authorities, and there are many difficulties associated with interpreting data from spontaneous reporting schemes.

Finally, as is stated clearly in our paper, it is possible that the association may be explained by factors such as confounding by concomitant disease and disease severity. Interestingly, the rate of cardiac failure associated with bambuterol in the first month of treatment was higher than for 11 cardiovascular drugs previously studied by PEM (table 1). Only two cardiac drugs, including the inotropic sympathomimetic xamoterol, have different advantages and disadvantages and, in general, one system cannot be relied upon to provide all the evidence needed. This point also applies to the fourth comment. In particular, it should be noted that there is gross under-reporting of suspected adverse drug reactions to the Committee on Safety of Medicines and other regulatory authorities, and there are many difficulties associated with interpreting data from spontaneous reporting schemes.

Finally, as is stated clearly in our paper, it is possible that the association may be explained by factors such as confounding by concomitant disease and disease severity. Interestingly, the rate of cardiac failure associated with bambuterol in the first month of treatment was higher than for 11 cardiovascular drugs previously studied by PEM (table 1). Only two cardiac drugs, including the inotropic sympathomimetic xamoterol, have different advantages and disadvantages and, in general, one system cannot be relied upon to provide all the evidence needed. This point also applies to the fourth comment. In particular, it should be noted that there is gross under-reporting of suspected adverse drug reactions to the Committee on Safety of Medicines and other regulatory authorities, and there are many difficulties associated with interpreting data from spontaneous reporting schemes.

Finally, as is stated clearly in our paper, it is possible that the association may be explained by factors such as confounding by concomitant disease and disease severity. Interestingly, the rate of cardiac failure associated with bambuterol in the first month of treatment was higher than for 11 cardiovascular drugs previously studied by PEM (table 1). Only two cardiac drugs, including the inotropic sympathomimetic xamoterol, have different advantages and disadvantages and, in general, one system cannot be relied upon to provide all the evidence needed. This point also applies to the fourth comment. In particular, it should be noted that there is gross under-reporting of suspected adverse drug reactions to the Committee on Safety of Medicines and other regulatory authorities, and there are many difficulties associated with interpreting data from spontaneous reporting schemes.
Non-Hodgkin’s lymphoma with CFA

We read with interest the case report by Orchard et al on non-Hodgkin’s lymphoma arising in cryptogenic fibrosing alveolitis (CFA).7 Although the authors state that this has not been described previously, we recently reported six cases of pulmonary B cell non-Hodgkin’s lymphomas arising in patients with autoimmune disorders, three of whom had CFA.2 As in the case described by Orchard et al, prognosis in these three patients was much poorer than that in the patients with high grade pulmonary non-Hodgkin’s lymphomas unassociated with CFA, presumably due to the combined effects of the two diseases.

ANDREW NICHOLSON
BRYAN CORRIN
Department of Histopathology,
Royal Brompton Hospital,
Sydney Street,
London SW3 6NP,
UK


AUTHOR’S REPLY
We are grateful to Dr Nicholson and Professor Corrin for pointing out their very interesting report, which was published after the original writing of our case report.

In the patient we reported the association was with cryptogenic fibrosing alveolitis (CFA) alone whereas, interestingly, the three patients they report had CFA associated with other systemic autoimmune disorders. The fact that CFA alone may be associated with B cell lymphomas, and the poorer prognosis seen by Nicholson and Corrin in their patients, as well as ours, supports the hypothesis that chronic local stimulation of the lymphoid system may play an important part in the aetiology and prognosis of these tumours.

T R ORCHARD
C D ERAUT
A G DAVISON
Southend Hospital, Westcliff on Sea,
Essex SS0 0RY,
UK

BOOK REVIEWS


A large amount of information has been packed into the 184 pages of this new guide-book in the Principles and Practice Series. This is a comprehensive review of the principles of ventilation and gas exchange with special emphasis on the implication of pulmonary function measurement during anaesthesia. The book details physiological principles and gives practical measurement guidance, with common sources of error, in the normal circumstances and during anaesthesia. The content is concise, the style direct and occasionally hard going. The text is clear and the diagrams are worth a special mention for their clarity and simplicity. This is not a textbook for beginners and requires a moderate familiarity with the principles of respiratory physiology, and the rules which govern respiratory mechanics and gas measurement. This guide represents excellent value for money and would be equally at home in the pulmonary function laboratory as well as the anaesthetics department.—SR


This is the third edition of an established book. Aiming to bring together all the recent information on basic mechanisms of asthma and also on clinical aspects and therapy in depth, this is achieved successfully. The scope of the book provides accessible reviews of all facets of asthma, from epidemiology and physiology to allergen avoidance, including recent developments in these fields. Modifications to the popular second edition include separate chapters on mediator antagonists and immunomodulators with consideration of the potential therapeutic benefits of intervening in the complex inflammatory and pharmacological pathways systematically covered in previous chapters. A new chapter on the pharmacoeconomics of asthma treatments provides a pertinent reminder that, after the wonders of basic science and the development of beneficial interventions, a wider perspective is required to successfully deliver benefits to those who require them. The addition of colour plates provides a welcome change to the previous black and white prints of the old edition which look a little drab in retrospect.

Well written by authorities in their fields and uniformly edited with an attractive presentation, this is an excellent book which succeeds in linking the rapidly developing body of knowledge on asthma with current treatment, while keeping the future constantly in mind.—AF

CORRECTION

Clinical features of non-smokers with α1-antitrypsin deficiency

The authors of the paper entitled “Clinical features and prognosis of life time non-smokers with severe α1-antitrypsin deficiency” by N Seersholm and A Kok-Jensen, which appeared on pages 265–8 of the April issue of Thorax, regret that some errors occurred in the text and in table 3. On page 267 the first line of column 1 should have read: “...50 years at entry was 56% compared with 50% for the subjects over 50 years...” Table 3 is reproduced here with the corrections shown in bold italics.

Table 3 Mean (SD) FEV1 % predicted and FEV1/FVC of index and non-index cases stratified by age at entry

<table>
<thead>
<tr>
<th>All age groups</th>
<th>Index cases</th>
<th>Non-index cases</th>
<th>p value (t test)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age at entry &lt;50 years</td>
<td>n = 8</td>
<td>n = 26</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>FEV1 (predicted)</td>
<td>56 (37)</td>
<td>100 (19)</td>
<td>0.53 (0.20)</td>
</tr>
<tr>
<td>FEV1/FVC</td>
<td>0.57 (0.18)</td>
<td>0.79 (0.13)</td>
<td>0.07 (0.34)</td>
</tr>
<tr>
<td>N (%) with FEV1 % pred ≤70%</td>
<td>20 (74%)</td>
<td>3 (8%)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Age at entry ≥50 years</td>
<td>n = 19</td>
<td>n = 14</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>FEV1 (predicted)</td>
<td>50 (20)</td>
<td>100 (24)</td>
<td>0.58 (0.17)</td>
</tr>
<tr>
<td>FEV1/FVC</td>
<td>0.40 (0.22)</td>
<td>0.57 (0.16)</td>
<td>0.71 (0.17)</td>
</tr>
<tr>
<td>N (%) with FEV1 % pred ≤70%</td>
<td>16 (84%)</td>
<td>1 (7%)</td>
<td>&lt;0.001</td>
</tr>
</tbody>
</table>